Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin + rituximab in relapsed/refractory aggressive NHL
NCT01232556Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2011
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Pfizer. Primary endpoints: Overall Survival at 5 years and Treatment Emergent Adverse Events at 20 weeks. Started Apr 2011; status: terminated.
02
Drugs
inotuzumab ozogamicin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01232556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232556.